Extrachromosomal DNA

Boundless Bio Announces Presentations at Additional Conferences in February

Retrieved on: 
Tuesday, February 18, 2020
Biotechnology, Genetics, Health, Oncology, DNA, Boundless, SVB Leerink, Hornby, Extrachromosomal DNA, Companies, Economy of the United States, ecDNA, Boundless Bio

Boundless Bio , a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced presentations at the following upcoming conferences this month:

Key Points: 
  • Boundless Bio , a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced presentations at the following upcoming conferences this month:
    16th UC San Diego Moores Cancer Center Industry/Academia "Next Generation Precision Oncology" Symposium : Zachary Hornby, President and Chief Executive Officer of Boundless Bio, will speak during a session devoted to solid tumors.
  • 9th Annual SVB Leerink Global Healthcare Conference: Zachary Hornby, President and Chief Executive Officer of Boundless Bio, will provide a company overview at 2:00 p.m. EST on Tuesday, February 25, 2020 in New York, New York.
  • Biocoms Annual Global Life Sciences Partnering Conference : Scott Moorefield, Ph.D., Chief Business Officer of Boundless Bio, will present a company overview at 11:45 a.m. PST on Wednesday, February 26, 2020 in La Jolla, California.
  • Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio Announces Presentations at Upcoming February Conferences

Retrieved on: 
Tuesday, February 4, 2020
Research, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, DNA, Medicine, Clinical medicine, Biotechnology, Extrachromosomal DNA, Cancer, Biomarker, Branches of biology, ecDNA, Boundless Bio

Boundless Bio , a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced presentations at the following upcoming conferences this month:

Key Points: 
  • Boundless Bio , a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced presentations at the following upcoming conferences this month:
    5th Annual Biomarker and Companion Diagnostics Conference : Jason Christiansen, Ph.D., Chief Technology Officer of Boundless Bio, will give a presentation titled: Targeting extrachromosomal DNA (ecDNA), a new approach to treating cancers with high copy number gene amplification.
  • The presentation will take place at 3:25 p.m. PST on Friday, February 7, 2020 in San Diego, California.
  • BIO CEO & Investor Conference : Zachary Hornby, President and Chief Executive Officer of Boundless Bio, will provide an overview of the companys efforts to pioneer novel cancer therapeutics directed to ecDNA.
  • Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio Announces Presentations at Two January Conferences

Retrieved on: 
Tuesday, January 7, 2020
Health, Biotechnology, Genetics, Oncology, Research, Science, General Health, DNA, Boundless, Extrachromosomal DNA, Cancer

Boundless Bio , a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced presentations at the following upcoming conferences:

Key Points: 
  • Boundless Bio , a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced presentations at the following upcoming conferences:
    2020 CTIC Pre-JPM 4th Healthcare Investment Summit : Scott Moorefield, Ph.D., Chief Business Officer of Boundless Bio, will give a company overview on Sunday, January 12, 2020, from 5:05 p.m. 5:20 p.m. PST.
  • Precision Medicine World Conference : Jason Christiansen, Ph.D., Chief Technology Officer of Boundless Bio, will give a presentation titled: Targeting Extrachromosomal DNA (ecDNA), A New Approach To Targeting Cancers With High Copy Number Amplification.
  • The presentation will take place during the Emerging Therapeutics Showcase on January 24, 2020, at 2:15 p.m. PST.
  • Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio to Present at the Piper Jaffray 31st Annual Healthcare Conference

Retrieved on: 
Monday, December 2, 2019
Biotechnology, Genetics, Health, Oncology, Extrachromosomal DNA, Boundless, DNA, ecDNA, Boundless Bio

Boundless Bio , a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that it will present at the Piper Jaffray 31st Annual Healthcare Conference in New York, NY.

Key Points: 
  • Boundless Bio , a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that it will present at the Piper Jaffray 31st Annual Healthcare Conference in New York, NY.
  • Zachary Hornby, President and Chief Executive Officer of Boundless Bio, will give a company overview on Thursday, Dec. 5, 2019 from 2:50 3:10 p.m. EST.
  • Extrachromosomal DNA, or ecDNA, are large circles of DNA containing genes that are outside the cells chromosomes and can make many copies of themselves.
  • Boundless Bio is a biotechnology company committed to interrogating a previously unexplored dimension in cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio Announces Publication in Nature Elucidating the Role of Extrachromosomal DNA (ecDNA) Structure in Cancer Biology

Retrieved on: 
Wednesday, November 20, 2019
Oncology, Health, Genetics, Research, Science, Biotechnology, DNA, Branches of biology, Medical genetics, Extrachromosomal DNA, Biology, Genetics, Cancer, Oncogenomics, Life sciences, ecDNA, Boundless Bio

Ludwig Professor of Cancer Genomics and Genetics, Stanford University; and Roel Verhaak, Ph.D., Professor and Associate Director of Computational Biology, The Jackson Laboratory.

Key Points: 
  • Ludwig Professor of Cancer Genomics and Genetics, Stanford University; and Roel Verhaak, Ph.D., Professor and Associate Director of Computational Biology, The Jackson Laboratory.
  • Boundless Bio scientists Kristen Turner, Ph.D. and Nam Nguyen, Ph.D. were co-lead authors on the manuscript as well.
  • Extrachromosomal DNA, or ecDNA, are large circles of DNA containing genes that are outside the cells chromosomes and can make many copies of themselves.
  • Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio to Present at Two October Conferences

Retrieved on: 
Wednesday, October 16, 2019
Biotechnology, Health, Oncology, Branches of biology, Extrachromosomal DNA, Biotechnology, Biology, Boundless, Chromosome, DNA, ecDNA, Boundless Bio

The presentation will take place at 3:00 p.m. EDT on Wednesday, Oct. 23, 2019 in Boston, Massachusetts.

Key Points: 
  • The presentation will take place at 3:00 p.m. EDT on Wednesday, Oct. 23, 2019 in Boston, Massachusetts.
  • 2019 BIO Investor Forum : Zachary Hornby, President and Chief Executive Officer of Boundless Bio, will give a company overview on Wednesday, Oct. 23, 2019 at 2:00 p.m. PDT in San Francisco, California.
  • Extrachromosomal DNA, or ecDNA, are large circles of DNA containing genes that are outside the cells chromosomes and can make many copies of themselves.
  • Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio Launches to Deliver Transformative Therapies to Patients with Difficult-to-Treat Cancers Driven by Extrachromosomal DNA

Retrieved on: 
Thursday, September 19, 2019
Research, Genetics, Biotechnology, Pharmaceutical, Health, Oncology, Science, DNA, Boundless, Cancer, Extrachromosomal DNA, ecDNA, Boundless Bio

Boundless Bio, a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced the completion of a $46.4 million Series A financing.

Key Points: 
  • Boundless Bio, a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced the completion of a $46.4 million Series A financing.
  • Boundless Bio has brought together a team of pioneering, committed, and collaborative individuals to tackle the hardest-to-treat cancers.
  • We have tremendous confidence in their ability to create life-improving therapies for patients with previously intractable cancers.
  • Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

LineaRx Achieves Higher Expression and Survival Rates in Human T Cells Transfected Non-Virally with Linear DNA

Retrieved on: 
Monday, April 29, 2019
Stem cells, Health, Biotechnology, Clinical trials, Genetics, Hospitals, Infectious diseases, Oncology, Branches of biology, Biology, Molecular biology, Life sciences, Biotechnology, Gene delivery, Plasmid, Polymerase chain reaction, DNA, Recombinant DNA, Extrachromosomal DNA

LineaRx, Inc. ( the Company) a wholly owned subsidiary of Applied DNA Sciences , Inc. (NASDAQ: APDN), announced today that it has improved expression levels and survival rates of linear DNA constructs delivered without viruses or plasmids to human T cells.

Key Points: 
  • LineaRx, Inc. ( the Company) a wholly owned subsidiary of Applied DNA Sciences , Inc. (NASDAQ: APDN), announced today that it has improved expression levels and survival rates of linear DNA constructs delivered without viruses or plasmids to human T cells.
  • We can now see that therapeutic doses are well within our planned range of numbers of redirected T cells.
  • The Company recently announced the first anti-CD19 expression in human T cells from a gene construct utilizing linear DNA produced via a scalable PCR manufacturing process.
  • Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria.